Latest "Zenobia Therapeutics" News Stories - Page: 5

23:25 EDT 17th October 2018 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 101–125 of 7,700+

Probably Relevant

This Day That Year: G1 Therapeutics

Shares of G1 Therapeutics Inc. (GTHX) have returned a whopping 230% over the last 1 year while the iShares NASDAQ Biotechnology Index (ETF) has gained a mere 11% during the same period.

In The Spotlight: Novus Therapeutics

Shares of Novus Therapeutics (NVUS) are up an impressive 47% so far this month while the iShares Nasdaq Biotechnology Index (ETF)(IBB) is up a mere 3% for the same period.

Why Pluristem Therapeutics believe that in cell therapy “the process is the product”

Karine Kleinhaus, Divisional Vice President, North America, Pluristem Therapeutics

Will Axsome Therapeutics Make Big Strides?

Shares of Axsome Therapeutics Inc. (AXSM) have returned 15% so far this month while the iShares Nasdaq Biotechnology ETF (IBB) has gained just 3% for the same period.

Neon Therapeutics files for IPO

Neon Therapeutics Inc. (immuno-oncology) filed for its initial public offering.

United Therapeutics to Co-Develop MannKind's Dry Powder Treprostinil for PAH

United Therapeutics has agreed to license and co-develop MannKind’s clinical-phase dry powder formulation of the pulmonary arterial hypertension (PAH) treatment treprostinil—the active ingredient in United Therapeutics’ top-selling drugs Remodulin® and Tyvaso®—through a collaboration that could generate more than $95 million for MannKind, the companies said today. Under their...

Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum

Drug makers are making more bets on the nascent field of digital medicine. The latest example: Click Therapeutics announced Monday that it grabbed a $17 million investment led by Sanofi Ventures, the Cambridge, MA-based venture capital arm of the French pharmaceutical giant. New York-based Click Therapeutics develops mobile apps intended to be prescribed by doctors […]

United Therapeutics to purchase SteadyMed in $216m deal

US-based biotechnology company United Therapeutics has signed a definitive merger agreement to buy SteadyMed for a total consideration of $216m,...Read More... The post United Therapeutics to purchase SteadyMed in $216m deal appeared first on Pharmaceutical Technology.

MannKind and United Therapeutics to advance dry powder treprostinil

US-based biopharmaceutical company MannKind has entered an exclusive licensing and collaboration agreement with United Therapeutics over a dry powder formulation...Read More... The post MannKind and United Therapeutics to advance dry powder treprostinil appeared first on Pharmaceutical Technology.

e-Therapeutics and C4X Discovery to collaborate on Parkinson's Disease treatment

The collaboration will see e-therapeutics combine its Network-Driven Drug Discovery (NDD) platform with C4XD's Taxonomy3 technology

vTv Therapeutics shares soar on licensing tie-up with Chinese group Newsoara Biopharma

Newsoara will develop vTv Therapeutics' HPP737 as a new treatment for chronic obstructive pulmonary disease

Have You Checked Checkpoint Therapeutics Yet?

Shares of Checkpoint Therapeutics Inc. (CKPT), a majority controlled subsidiary of Fortress Biotech Inc. (FBIO), are well off their highs recorded last September, and trade around $3.

LNC Therapeutics gets IP from Cornell

LNC Therapeutics licensed exclusive rights to Christensenella patents from Cornell University.

BriaCell Therapeutics announces positive proof of concept data in treating breast cancer

Briacell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V) CEO William Williams speaks with Proactive Investor's Christine Corrado at the MicroCap Conference in New York. BriaCell Therapeutics Corp. is an immuno-oncology company which develops immunotherapy treatments for cancer. BriaCell is currently focused on the clinical development of Bria-IMT™ as a 2nd line treatment for patients with adva...

e-Therapeutics (ETX) - Keeping the faith

Edison Investment Research - Pharmaceutical & healthcare - e-Therapeutics: e-Therapeutics’ (ETX) H118 results were a routine financial update highlighting its continuing focus on partnering the Network-driven Drug Discovery (NDD) platform, out-licensing its NDD-derived preclinical immunoncology (I/O) assets and financial prudence. The H118 operating loss was £2.8m. Cash outflow was &po...

Casma Therapeutics raises $58.5m in Series A funding

Third Rock Ventures has launched Casma Therapeutics with a $58.5m investment to harness the cellular process of autophagy to develop breakthrough therapies.

TG Therapeutics and Novimmune Forge $185M Agreement

TG Therapeutics and Novimmune SA struck a collaborative deal worth up to $185 million on the development and commercialization of a treatment for hematologic B-cell malignancies.

Modus Therapeutics raises $15.7M to fund sickle cell candidate trials

A Series A funding round brought in about $15.7 million for Swedish biotech Modus Therapeutics, which the company will use to -More- 

Sunascen Therapeutics LLC Announces a New Line of OTC Pain Relievers in Addition to a ...

ROCKVILLE, Md., Aug. 31, 2018 /PRNewswire/ -- At Sunascen Therapeutics, we are well aware of the long term effects from the chronic use of various Read more...

e-Therapeutics (ETX) - A matter of time until prime time

Edison Investment Research - Pharmaceutical & healthcare - e-Therapeutics: With the refocusing of the business and the new CEO’s strategic review now implemented, e-Therapeutics (ETX) finds itself with the NDD platform and at least two lead preclinical small molecule immuno-oncology (I/O) assets at a time when big pharma partners are clamouring for those assets. This is because Merck and BMS...

FDA Halts Plan for Vertex, CRISPR Therapeutics Sickle Cell Study

A Vertex Pharmaceuticals partnership with CRISPR Therapeutics to test a genetically engineered drug in patients as a treatment for sickle cell disease has been dealt a setback. The FDA placed a clinical hold on the application that Vertex (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) submitted to start human studies, the companies announced Wednesday after […]

Kite partners with HiFiBiO Therapeutics for TCR-based cancer therapies

Gilead Sciences’ subsidiary Kite has signed a research collaboration and licence agreement with biotechnology company HiFiBiO Therapeutics to help develop...Read More... The post Kite partners with HiFiBiO Therapeutics for TCR-based cancer therapies appeared first on Pharmaceutical Technology.

ADC Therapeutics doses first patient in Phase II trial of ADCT-402

ADC Therapeutics has dosed the first patient in a Phase II clinical trial to examine the efficacy and safety of...Read More... The post ADC Therapeutics doses first patient in Phase II trial of ADCT-402 appeared first on Drug Development Technology.

iCo Therapeutics Provides Corporate Update

Vancouver, British Columbia--(Newsfile Corp. - October 2, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today announced several positive corporate developments and u...

Athenex Announces Axis Therapeutics Enters into MOU with Hong Kong Polytechnic University

Athenex (NASDAQ:ATNX) has announced that Axis Therapeutics has entered into an MOU with the Kong Kong Polytechnic University to explore the establishment of a joint research center to advance the application of immunotherapy in Kong Kong. As quoted in the press release: Axis Therapeutics, a newly established joint venture to be owned as 55% by … Continued The post Athenex Announces Axis Ther...

Quick Search


News Quicklinks